A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects
Sign Up to like & getrecommendations! Published in 2019 at "BMC Pharmacology & Toxicology"
DOI: 10.1186/s40360-019-0376-9
Abstract: Background/objectiveFKB327 is a biosimilar of the adalimumab reference product (RP). The primary objective was to assess the relative bioavailability of FKB327 after a single subcutaneous (SC) dose via prefilled syringe (PFS), auto-injector (AI), or vial… read more here.
Keywords: assess relative; relative bioavailability; fkb327; syringe ... See more keywords